Interim report January-June 2017
Business highlights second quarter 2017 · Completed clinical program for CAM2038 in opioid dependence. · Positive clinical results from Phase 3 long-term safety study of CAM2038 in opioid dependence. · Positive initial Phase 1a results for weekly setmelanotide FluidCrystal® under development for treatment of genetic obesity disease by Rhythm. · Publication of clinical results for CAM2038 in JAMA Psychiatry and Journal of Substance Abuse Therapy. · Four presentations about CAM2038 for treatment of opioid dependence at the CPDD Annual Meeting in Montreal, June 2017. ·